CalciMedica (NASDAQ:CALC) Issues Quarterly Earnings Results

CalciMedica (NASDAQ:CALC) released its quarterly earnings data on Tuesday. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.17), Zacks reports.

CalciMedica Trading Down 5.7%

Shares of NASDAQ:CALC opened at $0.62 on Thursday. The stock has a market capitalization of $9.79 million, a PE ratio of -0.46 and a beta of 0.91. CalciMedica has a 1 year low of $0.46 and a 1 year high of $7.20. The firm has a fifty day moving average price of $0.82 and a 200 day moving average price of $0.81.

Analysts Set New Price Targets

A number of research firms recently issued reports on CALC. HC Wainwright reissued a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. Weiss Ratings upgraded CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Finally, UBS Group reissued a “neutral” rating on shares of CalciMedica in a research note on Thursday. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $10.00.

Insiders Place Their Bets

In related news, Director Fred A. Middleton purchased 248,972 shares of CalciMedica stock in a transaction on Thursday, June 25th. The stock was bought at an average price of $0.80 per share, with a total value of $199,177.60. Following the completion of the transaction, the director directly owned 1,063,272 shares of the company’s stock, valued at approximately $850,617.60. This represents a 30.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 28.25% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CalciMedica

A number of large investors have recently added to or reduced their stakes in the stock. Cetera Investment Advisers boosted its stake in CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares during the period. Renaissance Technologies LLC raised its stake in CalciMedica by 26.1% during the 4th quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock valued at $582,000 after purchasing an additional 18,300 shares during the last quarter. Jane Street Group LLC acquired a new position in CalciMedica during the 4th quarter valued at $127,000. Envestnet Asset Management Inc. boosted its holdings in CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares during the period. Finally, Boothbay Fund Management LLC bought a new stake in CalciMedica in the 4th quarter valued at $506,000.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.